Vivos Therapeutics, Inc. (NASDAQ: VVOS) has extended its strategic financing agreement with Streeterville Capital, LLC through August 31, 2026, according to a press release from the Littleton, Colorado-based medical device company.

Under the extended terms, Streeterville reaffirmed its commitment to convert up to $4.5 million of outstanding debt into a combination of perpetual, non-convertible preferred stock and shares of Vivos common stock. The conversion is structured to begin once Vivos raises $2.6 million in equity and can continue up to the $4.5 million maximum.

The original agreement, announced earlier in June 2026, set a deadline of June 15. Vivos said that timeframe was too short to complete its planned equity raise in an organized manner, prompting the extension.

The extended arrangement is also intended to allow a previously announced rights offering to commence within the new timeframe. Vivos stated the structure supports its plan to strengthen stockholders' equity and maintain compliance with Nasdaq continued listing standards.

"The extra time will allow the Company to raise the needed equity in an organized fashion and to allow the announced rights offering to start during that timeframe," said R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos Therapeutics.